// App-Quantinova.ai

4021 : Phase II study of chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer.

Researchers

Presenter

  • Tomoya Yokota

Principal Investigators

  • Yasuo Hamamoto

  • Yasuhiro Tsubosa

  • Hirofumi Ogawa

  • Yoshinori Ito

  • Hiroki Hara

  • Takashi Ura

  • Takashi Kojima

  • Keisho Chin

  • Shuichi Hironaka

  • Takayuki Kii

  • Yasushi Kojima

  • Yasunori Akutsu

  • Hisayuki Matsushita

  • Kentaro Kawakami

  • Keita Mori

  • Yushi Nagai

  • Chika Asami

  • Yuko Kitagawa

Medical Centers

  • Shizuoka Cancer Center, Sunto-Gun, Japan

  • Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  • Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan

  • Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan

  • Division of Radiation Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan

  • Radiation Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  • Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan

  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa, Japan

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan

  • Cancer Chemotherapy Center, Osaka Medical College Hospital, Osaka, Japan

  • Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan

  • Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Japan

  • Department of Surgery, Tochigi Cancer Center, Tochigi, Japan

  • Tochigi Cancer Center, Utsunomiya, Japan

  • Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan

  • Clinical Data Management, Clinical Research Data Center, National Cancer Center Hospital, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Adrucil injection

  • Docetaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved